Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
EKF Diagnostics Holdings ( (GB:EKF) ) just unveiled an announcement.
EKF Diagnostics Holdings has executed a share buyback of 141,000 ordinary shares at a weighted average price of 25 pence, with the repurchased stock to be held in treasury. Following this transaction, the company’s issued share capital stands at 435,383,092 shares, of which 3,560,980 are in treasury, leaving 431,822,112 shares carrying voting rights, a key reference point for investors monitoring disclosure thresholds.
As part of the buyback, EKF acquired 41,000 shares from funds managed by Harwood, including Oryx International Growth Fund and North Atlantic Smaller Companies Investment Trust, to keep Non-Executive Director Christopher Mills’ indirect interest from exceeding 30% of voting rights. After this adjustment, Mills’ aggregate indirect holding is 127,340,000 shares, underscoring the company’s active management of its capital structure and major shareholder positions within UK market regulations.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £26.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
Spark’s Take on GB:EKF Stock
According to Spark, TipRanks’ AI Analyst, GB:EKF is a Neutral.
EKF Diagnostics Holdings receives a score of 67, driven by strong financial performance and a positive earnings call. The company’s robust balance sheet and improved profitability are significant strengths. However, technical indicators suggest potential bearish momentum, and the valuation is moderate. The positive outlook from the earnings call, including strategic growth plans and a share buyback program, enhances the overall score.
To see Spark’s full report on GB:EKF stock, click here.
More about EKF Diagnostics Holdings
EKF Diagnostics Holdings is an AIM-listed global diagnostics business focused on point-of-care analysers in hematology and diabetes, as well as life sciences services that manufacture specialist enzymes and custom products for diagnostic, food and industrial applications. Headquartered in Penarth near Cardiff, the company operates five manufacturing sites across the U.S. and Germany and sells into more than 120 countries worldwide.
Average Trading Volume: 263,095
Technical Sentiment Signal: Sell
Current Market Cap: £112.3M
For an in-depth examination of EKF stock, go to TipRanks’ Overview page.